Roth MKM Sticks to Its Buy Rating for Gain Therapeutics (GANX)

Tip Ranks
2025.11.13 13:06
portai
I'm PortAI, I can summarize articles.

Roth MKM's Boobalan Pachaiyappan reiterated a Buy rating for Gain Therapeutics with a $6.00 price target. Despite Pachaiyappan's average return of -10.0% and a 34.31% success rate, the general analyst consensus is a Strong Buy with a $6.80 average price target for Gain Therapeutics.

In a report released today, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Gain Therapeutics, with a price target of $6.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Pachaiyappan covers the Healthcare sector, focusing on stocks such as Cingulate Inc, CervoMed, and PolyPid. According to TipRanks, Pachaiyappan has an average return of -10.0% and a 34.31% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gain Therapeutics with a $6.80 average price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.